Search Results
Your search for them matches 6128 pages
Showing 1 - 50Update to Patient–Clinician Communication Guideline Provides Recommendations on Telehealth, Boundary-Setting
ASCO has updated its guideline on patient–clinician communication, providing recommendations on a range of best practices for explaining treatment options and goals of care, conversing with patients’ support networks, communicating among care team members, and setting boundaries.1 The update to the ...
What Is the Optimal Setting for T-DXd in Early Breast Cancer? Experts Differ
Trastuzumab deruxtecan (T-DXd) has claimed a large share of the HER2-positive breast cancer landscape, even finding room among tumors previously thought to be HER2-negative. The DESTINY series of trials are international studies investigating T-DXd as a potential treatment option for eligible...
ASCO Expands TAPUR Trial With Two New Precision Drug Arms
ASCO has expanded its Targeted Agent and Profiling Utilization Registry (TAPUR™) study with two new developments: The study added its first antibody-drug conjugate (ADC), fam-trastuzumab deruxtecan-nxki (T-DXd), to determine if a wider group of patients would benefit from this medicine....
ASH/ISTH Create Guidelines for Pediatric VTE Prophylaxis
The American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) have released a set of comprehensive clinical practice guidelines for the use of anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism. The guidelines were...
New ASH HematOmics Program Offers Blood Cancer Data Integration Tool to Accelerate Research
In collaboration with St. Jude Children's Research Hospital and the Munich Leukemia Laboratory, the American Society for Hematology has introduced the ASH HematOmics Program (ASHOP), which may be one of the most comprehensive collections of blood cancer data ever to accelerate discovery, according...
Damaging Missense Variants in Innate Immunity Genes Linked to Earlier Breast Cancer Onset in BRCA1 Carriers
Damaging variants in genes involved in a rapid immune response (innate immunity) are significantly linked to earlier breast cancer onset in carriers of the BRCA1 genetic mutation, according to preliminary findings published by Shemesh et al in the Journal of Medical Genetics. The strongest...
NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient
The National Comprehensive Cancer Network® (NCCN®) brought together more than a thousand oncology professionals at the NCCN 2026 Annual Conference in Orlando, with hundreds more joining virtually. This year’s event featured educational sessions on breakthroughs in cancer prevention and treatment,...
Surgery Still Safe, Beneficial For Many Octogenarian Patients With NSCLC
Surgical treatment was found to be safe and demonstrate long-term quality-of-life benefits for carefully selected octogenarians with early-stage non–small cell lung cancer (NSCLC), according to findings from a prospective cohort study published in The Lancet Regional Health: Americas. “As our...
Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin
Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individuals were diagnosed with colorectal cancer, and approximately 53,000 individuals died from the...
Machine-Learning Model for HCC Risk Prediction May Outperform Current Methods
An interpretable machine-learning framework, called PRE-Screen-HCC, may predict risk levels for developing hepatocellular carcinoma (HCC) more accurately than publicly available risk scores, according to findings from a large population-based multicentric study published in Cancer Discovery. “Our...
Elinzanetant May Reduce Side Effects of Endocrine Therapy Among Patients With Breast Cancer
Results from the OASIS 4 clinical trial showed that elinzanetant, a neurokinin-targeted therapy, relieved hot flashes and night sweats that can occur because of menopause or hormone treatment for breast cancer. These findings were published in June 2025 in The New England Journal of Medicine. Now,...
Two Major Cancer Centers Announce Appointments of New Directors
Last week, Dartmouth Cancer Center (DCC) and Fox Chase Cancer Center announced the appointments of new directors—both experts in the treatment of lung cancer. DCC has appointed Roy S. Herbst, MD, PhD, as the center’s sixth director. Temple Health announced the appointment of Robert A. Winn, MD, as...
AI Use in Cancer Diagnosis, Prognosis, and Treatment: Are We There Yet?
The promise of artificial intelligence (AI) technologies to provide highly personalized oncology care for patients and improve outcomes has been decades in the making. In a 1987 editorial in The New England Journal of Medicine, pioneering nephrologist and health economist William B. Schwartz, MD,...
How AI Is Already Having a Significant Impact on Cancer Care
Three education sessions presented during the 2025 ASCO Annual Meeting showcased how artificial intelligence (AI) is quickly transforming cancer care from clinical trial planning and ambient scribes transcribing physician-patient conversations to therapeutic decision-making. The meeting also...
Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis
Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers have found a combination of the tyrosine kinase inhibitor tucatinib and the monoclonal antibody trastuzumab, plus the chemotherapy capecitabine, may improve symptoms and extend survival in some...
Activity Observed With Novel KRAS Inhibitor in Pancreatic Cancer
A novel KRAS G12D inhibitor produced disease control in almost 80% of patients with heavily pretreated advanced or metastatic KRAS G12D–mutated pancreatic cancer in an early-phase study reported at the 2026 ASCO Gastrointestinal Cancers Symposium. Of 41 evaluable patients treated with single-agent...
Structured Exercise Plan for Patients With Cancer May Reduce Cognitive Effects of Chemotherapy
A structured exercise program in patients with cancer receiving chemotherapy led to a reduction in self-reported cognitive impairment vs those receiving chemotherapy who were not on an exercise plan, according to findings from a nationwide, randomized phase III trial published in JNCCN—Journal of...
Stanford Names Leader for Drug Development and Precision Oncology
Vivek Subbiah, MD, has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026. In this role, he will lead the Early Drug Development Program to expand access to innovative treatments...
Activity Observed with Novel KRAS Inhibitor in Pancreatic Cancer
A novel KRAS G12D inhibitor produced disease control in almost 80% of patients with heavily pretreated advanced or metastatic KRAS G12D–mutated pancreatic cancer in an early-phase study reported at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium.1 Of 41 evaluable patients treated with...
Research Suggests AI Pathology Models May Take Unreliable 'Shortcuts' to Identify Cancer Biomarkers
Artificial intelligence (AI) tools that detect molecular biomarker status from histologic images may be dependent upon correlational relationships with clinicopathologic features, preventing the models from learning the true causal effect of the biomarker, according to findings published in Nature...
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsored by a pharmaceutical company with an interest in prostate cancer treatments, extolled the virtues ...
How the Outlook on Fertility Preservation for Patients With Cancer Is Improving
Each year in the United States, about 90,000 adolescents and young adults (AYAs), ages 15 to 39, are diagnosed with cancer,1 and they are immediately faced with myriad challenges and disruptions in their life stages, including psychosocial distress; interruptions in their education, career, and...
I Used AI to Supplement My Oncology Care—It Reshaped My Treatment Plan
A year ago, I was confronting a series of symptoms—including rapid weight loss, abdominal distress, fatigue, and heart issues—that I couldn’t explain. I was just 60 years old and had been in good health, but now I sensed that something was seriously wrong. I made appointments with my primary care...
Introducing ASCO AI in Oncology
In February, ASCO and Conexiant launched ASCO AI in Oncology (ascoai.org), a digital platform dedicated to understanding how artificial intelligence (AI) is impacting cancer care. “Our goal with this hub is to empower oncology professionals with knowledge and the tools to adapt to a rapidly...
Adding Encorafenib and Cetuximab to FOLFIRI Shows Benefit in BRAF-Mutant Colorectal Cancer
The addition of the BRAF inhibitor encorafenib and the EGFR antibody cetuximab to chemotherapy with FOLFIRI (leucovorin, fluorouracil, and irinotecan) in the first-line treatment of BRAF V600E–mutated metastatic colorectal cancer led to a significant improvement in overall response rate—compared...
Cancer Surgery Outcomes Similar Between Rural and Urban Facilities
Patients in rural areas who received surgery locally for their lung or colon cancer had comparable surgical outcomes and mortality rates to patients who underwent surgery in an urban facility, according to the results of an analysis published in the Journal of the American College of Surgeons....
FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
The U.S. Food and Drug Administration (FDA) has approved drug labeling changes to six menopausal hormone therapy products, also known as hormone replacement therapy (HRT), to clarify risk considerations for these drugs. Specifically, risk statements related to cardiovascular disease, breast cancer, ...
ASH Publishes Clinical Guidelines on AL Amyloidosis Diagnosis
The American Society of Hematology (ASH) has released clinical practice guidelines on the diagnosis of light chain (AL) amyloidosis, which were published in Blood Advances. Additionally, the expert panel behind the guidelines also published a scoping review about the clinical features of systemic...
GIMEMA ALL2820: Chemotherapy-Free Regimen Studied in Front-Line Setting
As front-line therapy, a chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed standard treatment with imatinib plus chemotherapy in adults with newly diagnosed Philadelphia chromosome–positive...
A Paradigm Shift in Treating Adult AML?
The scientific revolution in determining the genetic basis of cancer is finally bearing fruit in hematologic neoplasms such as acute myeloid leukemia (AML), where over the past decade a number of effective new drugs have expanded our armamentarium and provided effective—and in some cases...
Lymph Node Examination Should be Expanded to Accurately Assess Metastasis in NSCLC, Research Says
Breakthrough research presented at the 2026 Society of Thoracic Surgeons (STS) Annual Meeting shows that additional lymph node evaluation is needed during surgery for non–small cell lung cancer (NSCLC) to accurately identify cancer spread (Abstract A-1588). Globally, surgical standards vary on the...
Colorectal Cancer Liver Metastases: Transplant or Resect?
Colorectal metastases isolated to the liver no longer portend a universally fatal outcome. In 2024, the TransMet study1demonstrated that liver transplantation in select patients could be life-saving—thus changing the treatment paradigm—but so can surgical resection when appropriately applied....
Metastasis-Directed Therapy for Oligometastatic Prostate Cancer
Metastasis-directed therapy significantly improved progression-free survival, radiologic progression–free survival, and castration resistance–free survival in patients with oligometastatic prostate cancer, according to a new study published by Tang et al in The Lancet Oncology. The study is a...
World Cancer Day 2026: UICC’s Campaign ‘United by Unique’
As the organizer of World Cancer Day on February 4, the Union for International Cancer Control (UICC) is mobilizing organizations and individuals worldwide to ensure that the voices of people affected by cancer are heard and drive a new vision of cancer care. Now in its second year, the World...
Pirtobrutinib Improves Progression-Free Survival vs Bendamustine/Rituximab in Front-Line CLL/SLL
The first prospective, randomized phase III trial of a noncovalent Bruton’s tyrosine kinase (BTK) inhibitor exclusively in treatment-naive patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)—BRUIN CLL-313—demonstrated a statistically significant and clinically...
Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma
A response-adapted approach to treatment decision-making for patients with resectable cutaneous squamous cell carcinoma demonstrated that with the use of neoadjuvant pembrolizumab, many patients could avoid surgery and/or radiotherapy. Findings from the De-Squamate study were published in the...
Researchers Advance Understanding of Female Sexual Anatomy to Improve Pelvic Cancer Radiotherapy
A recent, innovative study provides radiation oncologists with practical guidance to identify and protect female sexual organs during pelvic cancer treatment. Published by Greenwald et al in Practical Radiation Oncology, the report’s authors address a long-standing gap in cancer care by bringing...
Is Long-Term PPI Use Associated With Increased Gastric Cancer Risk?
Long-term proton pump inhibitor (PPI) use may not be associated with an increased risk of gastric adenocarcinoma, according to findings from a Nordic health study published by Duru et al The BMJ. According to the report's authors, “This finding should offer relief for patients needing long-term...
CRI Launches Open Database for Immunotherapy Cancer Research
The Cancer Research Institute (CRI) in collaboration with 10x Genomics, Stanford University School of Medicine, the University of Pennsylvania Perelman School of Medicine, and Memorial Sloan Kettering Cancer Center, has launched an open foundational database for cancer immunotherapy research. The...
A Battle With My Blood
Editor’s note: On November 22, 2025—the 62nd anniversary of her grandfather President John F. Kennedy’s assassination—Tatiana Celia Kennedy Schlossberg published an essay in The New Yorker detailing her diagnosis of acute myeloid leukemia with chromosome 3 inversion, a rare and aggressive subtype...
Deb Schrag, MD, MPH, FASCO, Elected 2027–2028 ASCO President
On December 19, 2025, ASCO announced its members had elected Deb Schrag, MD, MPH, FASCO,as President for the 2027–2028 term. Dr. Schrag will begin her term as President-Elect upon the conclusion of the 2026 ASCO Annual Meeting. Dr. Schrag, a gastrointestinal medical oncologist, is the George J....
Evolving Treatment Landscape Spurs Living Guideline Update on Multiple Myeloma
ASCO, in collaboration with Ontario Health (Cancer Care Ontario), has published an update to their previous guideline on the treatment of multiple myeloma.1 This new guideline—which has been selected as an ASCO Living Guideline—reflects dramatic changes that have helped improve the management of...
Popular Supplement May Interfere With Cancer Treatment
For many patients with cancer, hair loss can be one of the most distressing side effects of their therapy. Increasingly, patients have been taking oral supplements of biotin, which are marketed to consumers for their potential to improve hair regrowth and brittle nails. However, there is little...
What Is Causing a Rise in Early-Onset Gastrointestinal Cancers, Including Pancreatic Cancer?
Although it’s been widely reported for years that colorectal cancer incidence has been increasing among younger adults under age 50 by between 1% and 2% annually since the mid-1990s,1 two new studies by Kimmie Ng, MD, MPH, Associate Chief of the Division of Gastrointestinal Oncology and Founding...
Can a Genetic Variant Affect the Efficacy of Abiraterone?
Data from a major clinical trial from the Alliance for Clinical Trials in Oncology have uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormonal treatment for advanced prostate cancer. Published by Norton et al in Clinical and Translational...
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
A deep learning model demonstrated the ability to predict breast cancer recurrence risk and possible benefit from the addition of chemotherapy based on histopathologic images rather than genomic testing in patients with hormone receptor–positive, HER2-negative breast cancer, according to findings...
Nivolumab Plus AVD Reduces Disease Progression Risk in Adolescents With Advanced Classical Hodgkin Lymphoma
A combination of nivolumab with AVD chemotherapy (doxorubicin, vinblastine, and dacarbazine) demonstrated a significant reduction in the risk of disease progression or death compared with brentuximab vedotin plus AVD in adolescent patients with newly diagnosed advanced classical Hodgkin lymphoma,...
Small Study Examines Potential of Artificial Saliva in Patients With Head and Neck Cancer
An artificial saliva in the form of a mouthwash, produced with a protein extracted from sugarcane and modified in a laboratory, may aid in treating hyposalivation among patients with head and neck cancer, a new study has found. Radiotherapy delivered very close to the mouth can destroy salivary...
Benefit of Azacitidine Plus Venetoclax Confirmed in AML
The combination of the hypomethylating agent azacitidine and the BCL2 inhibitor venetoclax is an established regimen in older, unfit patients with acute myeloid leukemia (AML). Now, a phase II randomized trial indicates potential for less intensive therapy in the newly diagnosed fit population. In...
Using AI to Ensure That All Patients With Cancer Have Access to Precision Oncology Care
Steve Brown, Founder and Chief Executive Officer of CureWise (curewise.com), an artificial intelligence (AI)-driven patient advocacy app, describes his year-long quest to understand a series of symptoms that ultimately led to a diagnosis of light chain (AL) amyloidosis—a disease closely related to ...
